Overview

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Status:
Completed
Trial end date:
2023-08-28
Target enrollment:
Participant gender:
Summary
The goal of this two-sequence, two-cycle, single and multiple-dose Phase I clinical trial is To evaluate the human bioequivalence of the test preparation and the reference preparation in 28 healthy chinese subjects at a single center.
Phase:
Phase 1
Details
Lead Sponsor:
Hangzhou Highlightll Pharmaceutical Co., Ltd